In response to the Marburg hemorrhagic fever outbreak that has claimed the lives of 12 individuals, Rwandan health authorities have initiated a vaccine study. The country received 700 doses of an experimental vaccine from the Sabin Vaccine Institute in the United States. The vaccination campaign will target health workers, emergency responders, and individuals who have been in contact with confirmed cases, as announced by the Health Ministry.
Marburg, a virus similar to Ebola, is believed to originate from fruit bats and spreads through close contact with infected individuals or contaminated surfaces. With no authorized vaccine or treatment available, the disease can be fatal in up to 88% of cases.
